RFK Jr., the MAHA Commission, and What It Means for Your Mental Health Medications
Psychiatric medication misinformation is spreading faster than ever — and for patients currently on antidepressants, mood stabilizers, or other psychiatric treatments, the noise can be genuinely alarming.
In 2025 and into 2026, high-profile claims from federal health officials have suggested that psychiatric medications are overprescribed, dangerous, or addictive in ways the evidence simply doesn’t support. Kennedy announced plans to wean Americans off antidepressants like Prozac and Zoloft, while falsely stating that the FDA’s black-box warning on SSRIs referred to “homicidal behavior” — when in fact it addresses suicidal thoughts in young people, a critical distinction.
Psychiatrists have widely described these characterizations as inaccurate and potentially harmful to patients who depend on these medications. For patients in Maryland, DC, and Virginia — where these policy conversations are especially close to home — the uncertainty is real. This post addresses the most common claims directly, with the evidence behind each one.
Fact-Checking the Claims
No ban on psychiatric medications exists — but the policy landscape has shifted.
No law or federal regulation bans or restricts patient access to antidepressants, mood stabilizers, or other psychiatric medications. These drugs remain legally available by prescription across the United States.
What has changed is the policy direction at HHS. In May 2026, HHS announced new clinical guidance and billing changes designed to encourage providers to help patients taper off SSRIs — framed as supporting patient autonomy, but criticized by many psychiatrists as potentially discouraging necessary treatment.
The practical implication for patients: your access to existing prescriptions is not at legal risk. But the broader conversation about psychiatric medications has become more politicized, which is exactly why accurate information matters more than ever.
Psychiatric Medications Are Clinically Proven and Safe
SSRIs and other psychiatric medications have decades of clinical research behind them. The American Psychiatric Association, the American Academy of Child and Adolescent Psychiatry, and major research institutions worldwide continue to support their use as evidence-based, often life-saving treatments for depression, anxiety, bipolar disorder, and ADHD.
Two specific concerns have circulated widely and deserve a direct response:
On addiction risk: “Antidepressants and heroin are in different universes when it comes to addiction risk,” says Keith Humphreys, psychiatry professor at Stanford. SSRIs can cause discontinuation symptoms when stopped abruptly — but discontinuation symptoms are not the same as addiction, which involves compulsive drug-seeking, tolerance, and craving. Antidepressants do not cause craving, tolerance, or loss of control over medication taking, and for this reason they are not regarded as addictive.
On the FDA warning: the black-box warning on SSRIs addresses suicidal thoughts in young people — not homicidal behavior. Characterizing it otherwise is a factual misreading of the regulatory language.
Decisions About Your Medications Should Be Made Between You and Your Provider
If you’re considering changing or stopping a psychiatric medication, the most important step is talking with your prescriber first. Stopping abruptly can cause discontinuation symptoms, increase relapse risk, or worsen symptoms — even when the intention is to reduce medication.
What the current policy environment does not change: your right to make informed decisions about your own care, with guidance from a clinician who knows your full picture. That conversation belongs in a clinical setting, not in a news cycle.
Why Misinformation is Harmful
When patients stop psychiatric medications based on fear rather than clinical guidance, the consequences can be serious — including relapse, hospitalization, and in some cases, crisis.
A 2024 systematic review published in Health Affairs — led by Harvard Medical School researchers — found that media amplification of FDA warnings about antidepressants led to a significant drop in depression treatment among young people, with an estimated nearly 6,000 additional suicide deaths in the first six years after the boxed warnings were issued.
Misinformation doesn’t just create fear. It creates distance between patients and care. If you’ve seen claims about psychiatric medications online and feel uncertain about your treatment, the right next step is a conversation with your provider — not a decision made based on a headline.
How to Evaluate Health Claims About Medications
When headlines about psychiatric medications create uncertainty, these steps help:
- Go to primary sources. The organizations with the most credible, up-to-date information on psychiatric medications include the American Psychiatric Association, the National Institute of Mental Health, and the FDA’s medication information database. If a claim contradicts what these organizations say, that’s a signal worth noting.
- Check who is making the claim — and what their expertise is. Political positions are not the same as clinical evidence. A statement from a federal official carries political weight but does not override decades of peer-reviewed research.
- Talk to your prescriber before making any changes. If something you read is creating real concern about your medication, bring it to the person who knows your history. That conversation is always more useful than a decision made based on a headline.
The Bottom Line
Misinformation about psychiatric medications is not new — but the current moment has amplified it in ways that are reaching patients directly. If you’re on medication that’s working, the most dangerous thing you can do is stop it based on a headline. If you have genuine questions about your treatment, those questions deserve a real clinical conversation — not an answer from social media.
Your medication decisions belong between you and your provider. That’s not a bureaucratic formality. It’s how safe, effective psychiatric care actually works.
You Don’t Have to Figure This Out Alone.
If reading about medication policies has left you feeling uncertain, anxious, or unsure about your own treatment, those feelings are valid — and they deserve a real conversation, not more scrolling.
Our providers are here to listen, answer your questions, and help you feel confident in your care plan. No judgment. No pressure.
👉 Explore Providers to Book an Appointment and Start Your Care Plan
(Note: Modyfi proudly accepts most major commercial insurance plans in MD, DC, VA, and WV; currently, we do not accept Medicare or Medicaid.)
FAQ
Should I stop taking my antidepressant because of what RFK said?
No — and this is worth being direct about. Stopping a psychiatric medication abruptly, or without clinical guidance, can cause discontinuation symptoms, increase the risk of relapse, and in some cases worsen the condition the medication was managing. That risk doesn’t change based on political statements.
If what you’ve read has raised genuine questions about your medication — whether it’s the right dose, whether it’s still working, or whether alternatives exist — those are legitimate questions worth exploring. But they belong in a conversation with your prescriber, not in a decision made based on a news cycle.
Your provider can review your current treatment, address your concerns, and help you make any changes safely if that’s the right direction. That’s what the clinical relationship is for.
Are SSRIs safe long-term?
For most people, yes — with appropriate monitoring. SSRIs have been studied extensively over decades, and the evidence supports their long-term safety for the majority of patients. Common side effects like nausea, sleep changes, or sexual dysfunction often improve over time or can be managed by adjusting the dose or switching medications.
That said, long-term use isn’t a one-size-fits-all decision. Some people take SSRIs indefinitely because their condition requires it. Others taper off after a defined treatment period with no recurrence. The right approach depends on the individual — their diagnosis, history, response to treatment, and personal goals.
What the evidence does not support is the idea that long-term SSRI use is inherently dangerous or that it causes the kind of dependence associated with opioids or other controlled substances. If you have concerns about your long-term medication plan, that conversation is best had with your prescriber rather than resolved by stopping unilaterally.
What are the actual side effects of antidepressants?
SSRIs and other antidepressants can cause side effects, and being honest about that is part of informed consent. The most commonly reported include nausea, headache, sleep disturbances, fatigue, dry mouth, and sexual side effects such as reduced libido or difficulty with orgasm. Most of these are most pronounced in the first few weeks of treatment and tend to improve as the body adjusts.
Less common but more significant side effects — such as increased anxiety or agitation in the early weeks, or suicidal thoughts in young people — are why close monitoring at the start of treatment matters, and why the FDA requires a black-box warning for patients under 25.
What antidepressants don’t cause: addiction, homicidal behavior, or the kind of physical dependence associated with opioids. Discontinuation symptoms can occur when stopping abruptly, which is why tapering under medical supervision is the standard approach.
If a side effect is affecting your quality of life, that’s worth raising with your provider. There are usually options — adjusting the dose, timing, or switching to a different medication — that can address the issue without abandoning treatment altogether.
